Sellas Life Sciences has seen significant stock volatility, with a 362% gain since January, fueled by speculation surrounding the REGAL Phase 3 trial for its leukemia treatment, galinpepimut-S. While a report suggested that the trial had reached a critical milestone, the company has not confirmed this, leading to a precarious trading environment. Meanwhile, Sellas experienced a legal setback in its partnership with 3D Medicines over milestone payments, although this had little impact on market sentiment.
Recent amendments to executive contracts have sparked takeover speculation, and institutional investors are increasing their stakes, with notable price target upgrades from analysts. However, Sellas reported a net loss of $9.61 million in Q2, raising concerns about its financial health ahead of anticipated clinical trial data. The stock’s sharp rise has made it vulnerable to potential downturns if the expected outcomes do not materialize.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/sellas-life-sciences-a-2-4-billion-valuation-built-on-an-unconfirmed/70016240
